F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comGland Pharma Ltd is one of India’s leading pharmaceutical companies, specializing in injectable medicines and sterile formulations. The company operates globally, supplying complex generic drugs to regulated markets such as the United States, Europe, and other international regions. Its strong presence in the injectables segment and focus on high-quality manufacturing have positioned it as a trusted partner for global healthcare companies.
With increasing demand for affordable generics, rising healthcare spending, and expansion into new markets, investors are closely tracking the Gland Pharma Ltd Share Price Target 2026 to 2030. While the stock has seen volatility after reaching its all-time high, its strong fundamentals and global business model provide a solid base for long-term growth potential.
| Year | Estimated Share Price Target (₹) |
|---|---|
| 2026 | ₹2,000 – ₹2,400 |
| 2027 | ₹2,300 – ₹2,800 |
| 2028 | ₹2,700 – ₹3,300 |
| 2029 | ₹3,200 – ₹3,900 |
| 2030 | ₹3,800 – ₹4,600 |
These projections are based on current fundamentals, industry growth trends, and business expansion potential.
| Metric | Value |
|---|---|
| Open | ₹1,689.00 |
| Previous Close | ₹1,670.20 |
| High | ₹1,727.00 |
| Low | ₹1,670.20 |
| 52 Week High | ₹2,131.00 |
| 52 Week Low | ₹1,277.80 |
| Market Cap | ₹28,181 Cr |
| Volume | 58,101 |
| VWAP | ₹1,709.56 |
| Beta | 0.77 |
| Book Value Per Share | ₹628.70 |
| Dividend Yield | 1.05% |
| Face Value | ₹1 |
| All Time High | ₹4,350.00 |
| All Time Low | ₹861.00 |
| 20D Avg Volume | 421,923 |
| 20D Avg Delivery (%) | 10.99 |
Gland Pharma Ltd is a research-driven pharmaceutical company focused primarily on injectable formulations. Its core business includes:
The company has a strong footprint in the United States, which contributes a significant portion of its revenue. It also partners with global pharmaceutical companies for manufacturing and development services.
Gland Pharma’s competitive advantage lies in its expertise in complex injectables, cost-efficient manufacturing, and regulatory approvals from major global agencies such as the USFDA.
With a market capitalization of ₹28,181 crore, Gland Pharma is categorized as a mid-cap pharmaceutical company. It offers a balance between growth potential and relative stability compared to small-cap stocks.
The book value per share is ₹628.70, indicating that the stock is trading at a premium, which reflects investor confidence in its future earnings potential.
The beta of 0.77 suggests that the stock is less volatile than the broader market, making it relatively stable during market fluctuations.
Overall, Gland Pharma has a solid financial foundation, supported by export-driven revenue and a niche business model.
| Shareholder Type | Holding (%) |
|---|---|
| Promoters | 51.83% |
| Mutual Funds | 31.42% |
| Retail & Others | 7.61% |
| Foreign Institutions | 7.58% |
| Other Domestic Institutions | 1.57% |
Insight: High institutional holding (mutual funds + FIIs) reflects strong confidence from professional investors.
Injectables are a growing segment in the pharmaceutical industry due to their effectiveness and hospital usage.
Gland Pharma earns a significant portion of its revenue from exports, especially the US, which offers higher margins.
Contract manufacturing is becoming a key growth driver, providing stable and scalable revenue streams.
The company is continuously working on new generic drug approvals, which can boost future revenue.
Cost-efficient manufacturing and economies of scale improve margins and profitability.
Pharmaceutical companies face strict regulations. Any adverse findings from regulators like USFDA can impact operations.
A large portion of revenue comes from the US, making the company vulnerable to policy changes.
Generic drug pricing pressure in global markets can affect margins.
Intense competition from global pharma companies may limit growth.
As an export-driven company, currency volatility can impact earnings.
| Target | ₹2,000 – ₹2,400 |
By 2026, the company is expected to benefit from steady growth in injectable drug demand and expansion in regulated markets.
Growth Drivers:
Investment Outlook:
Moderate to strong growth expected with relatively lower volatility compared to small-cap stocks.
| Target | ₹2,300 – ₹2,800 |
In 2027, increased capacity utilization and product pipeline expansion may drive revenue growth.
Growth Drivers:
Investment Outlook:
Positive outlook with steady earnings growth potential.
| Target | ₹2,700 – ₹3,300 |
By 2028, the company could experience accelerated growth if it successfully launches new products.
Growth Drivers:
Investment Outlook:
Growth phase with increasing investor interest.
| Target | ₹3,200 – ₹3,900 |
In 2029, the company may benefit from mature operations and improved profitability.
Growth Drivers:
Investment Outlook:
Potential for strong returns if growth momentum continues.
| Target | ₹3,800 – ₹4,600 |
By 2030, Gland Pharma could emerge as a dominant player in the injectable segment globally.
Growth Drivers:
Investment Outlook:
Suitable for long-term investors seeking stable growth in the pharma sector.
Gland Pharma Ltd appears to be a fundamentally strong company with a clear focus on a high-growth niche segment. Its global presence, strong institutional backing, and consistent performance make it a compelling option for long-term investors.
However, investors should keep in mind sector-specific risks such as regulatory challenges and pricing pressures. Overall, the company offers a balanced mix of growth and stability, making it suitable for medium to long-term portfolios.
Gland Pharma Ltd is a mid-cap pharmaceutical company with strong fundamentals and global operations. The Gland Pharma Ltd Share Price Target 2026 to 2030 indicates steady growth potential, with the stock possibly reaching ₹3,800–₹4,600 by 2030, driven by expanding global demand and operational strength.
The estimated target for 2026 is ₹2,000 to ₹2,400.
The projected share price target for 2030 is ₹3,800 to ₹4,600.
Yes, it can be considered a good long-term investment due to strong fundamentals and global business presence.
Key factors include regulatory approvals, global demand, financial performance, and currency fluctuations.
Yes, the company offers a dividend yield of around 1.05%.
This article is for educational and informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to risks, and investors should conduct their own research or consult a financial advisor before making any investment decisions.
Register & Login